The aim of this study was to evaluate the efficacy, safety and tolerability of lobaplatin versus carboplatin as neoadjuvant therapy for stage II / III HER-2 positive breast cancer.
Arms and Interventions Control group : Docetaxeor albumin paclitaxel combined with carboplatin for 6 cycles. Trastuzumab combined with pertuzumab : 6 cycles of treatment, according to the instructions recommended dosage.
Experimental group : Docetaxel or albumin paclitaxel combined with lobaplatin for 6 cycles. Trastuzumab combined with pertuzumab : 6 cycles of treatment, according to the instructions recommended dosage.
Newly diagnosed breast cancer
18-70 Years, female;
life expectancy is not less than 3 months
Histologically confirmed HER2 positive ( human epidermal growth factor receptor 2 [ HER2 ] positive, estrogen receptor [ ER ] and progesterone receptor [ PR ] negative or positive );
Stage Ⅳ (metastatic) breast cancer or bilateral breast cancer
Inflammatory breast cancer
patients who received chemotherapy, endocrine therapy, immunotherapy, biotherapy or TACE within 4 weeks before admission
Has participated in an interventional clinical study with an investigational compound within 4 weeks prior to initiation of study treatment
Shandong Cancer Hospital and Institute
Lead sponsor
Cancer Hospital Chinese Academy of Medical Science
Collaborator